RT Journal Article
SR Electronic
T1 Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP CD-19-0442
DO 10.1158/2159-8290.CD-19-0442
A1 Lee, Jeeyun
A1 Kim, Seung Tae
A1 Kim, Kyung
A1 Lee, Hyuk
A1 Kozarewa, Iwanka
A1 Mortimer, Peter GS
A1 Odegaard, Justin I
A1 Harrington, Elizabeth A
A1 Lee, Juyoung
A1 Lee, Taehyang
A1 Oh, Sung Yong
A1 Kang, Jung-Hun
A1 Kim, Jung Hoon
A1 Kim, Youjin
A1 Ji, Jun Ho
A1 Kim, Young Saing
A1 Lee, Kyoung Eun
A1 Kim, Jinchul
A1 Sohn, Tae Sung
A1 An, Ji Yeong
A1 Choi, Min-Gew
A1 Lee, Jun Ho
A1 Bae, Jae Moon
A1 Kim, Sung
A1 Kim, Jae J.
A1 Min, Yang Won
A1 Min, Byung-Hoon
A1 Kim, Nayoung K.D.
A1 Luke, Sally
A1 Kim, Young Hwa
A1 Hong, Jung Yong
A1 Park, Se Hoon
A1 Park, Joon Oh
A1 Park, Young Suk
A1 Lim, Ho Yeong
A1 Talasaz, AmirAli
A1 Hollingsworth, Simon J.
A1 Kim, Kyoung-Mee
A1 Kang, Won Ki
YR 2019
UL http://cancerdiscovery.aacrjournals.org/content/early/2019/07/17/2159-8290.CD-19-0442.abstract
AB The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify metastatic GC patients based on clinical sequencing and focused on eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, MET overexpression, all negative, TSC2 deficient, or RICTOR amplification) to assign patients to one of the 10 associated clinical trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET inhibitor), selumetinib (MEK inhibitor), adavosertib (WEE1 inhibitor), and vistusertib (TORC inhibitor) were tested with or without chemotherapy. 772 GC patients were enrolled and sequencing was successfully achieved in 715 patients (92.6%). When molecular screening was linked to seamless immediate access to parallel matched trials, 14.7% of patients received biomarker-assigned drug treatment. The biomarker-assigned treatment cohort had encouraging response rates and survival when compared to conventional 2L chemotherapy. ctDNA analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib.